{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T16:31:36Z","timestamp":1726849896501},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T00:00:00Z","timestamp":1562371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T00:00:00Z","timestamp":1562371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10620-019-05717-0","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T09:02:23Z","timestamp":1562403743000},"page":"3630-3641","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue"],"prefix":"10.1007","volume":"64","author":[{"given":"Lung-Yi","family":"Mak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze-Hang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond Yat-Hin","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny Ka-Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tak-Mao","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,6]]},"reference":[{"key":"5717_CR1","unstructured":"World Health Organization Fact Sheet on Hepatitis B. Volume 2017, 2017."},{"key":"5717_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cld.2004.02.003","volume":"8","author":"SH Han","year":"2004","unstructured":"Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis. 2004;8:403\u2013418.","journal-title":"Clin Liver Dis"},{"key":"5717_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-2008-1063929","volume":"1","author":"JL Dienstag","year":"1981","unstructured":"Dienstag JL. Hepatitis B as an immune complex disease. Semin Liver Dis. 1981;1:45\u201357.","journal-title":"Semin Liver Dis"},{"key":"5717_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00000441-197507000-00007","volume":"270","author":"DJ Gocke","year":"1975","unstructured":"Gocke DJ. Extrahepatic manifestations of viral hepatitis. Am J Med Sci. 1975;270:49\u201352.","journal-title":"Am J Med Sci"},{"key":"5717_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/ije\/dyh339","volume":"34","author":"G Chen","year":"2005","unstructured":"Chen G, Lin W, Shen F, et al. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol. 2005;34:132\u2013137.","journal-title":"Int J Epidemiol"},{"key":"5717_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5604\/16652681.1226813","volume":"16","author":"F Fabrizi","year":"2017","unstructured":"Fabrizi F, Donato FM, Messa P. Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis. Ann Hepatol. 2017;16:21\u201347.","journal-title":"Ann Hepatol"},{"key":"5717_CR7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/jvh.12733","volume":"24","author":"L Ning","year":"2017","unstructured":"Ning L, Lin W, Hu X, et al. Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. J Viral Hepat. 2017;24:1043\u20131051.","journal-title":"J Viral Hepat"},{"key":"5717_CR8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.jhep.2011.03.030","volume":"55","author":"S Mauss","year":"2011","unstructured":"Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235\u20131240.","journal-title":"J Hepatol"},{"key":"5717_CR9","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/ki.2014.363","volume":"87","author":"YC Chen","year":"2015","unstructured":"Chen YC, Su YC, Li CY, et al. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int. 2015;87:1030\u20131038.","journal-title":"Kidney Int"},{"key":"5717_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/cid\/cit642","volume":"58","author":"KN Ly","year":"2014","unstructured":"Ly KN, Xing J, Klevens RM, et al. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis. 2014;58:40\u201349.","journal-title":"Clin Infect Dis"},{"key":"5717_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/apt.13162","volume":"41","author":"R Rajbhandari","year":"2015","unstructured":"Rajbhandari R, Danford CJ, Chung RT, et al. HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease. Aliment Pharmacol Ther. 2015;41:928\u2013938.","journal-title":"Aliment Pharmacol Ther"},{"key":"5717_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3949\/ccjm.74.5.353","volume":"74","author":"G Appel","year":"2007","unstructured":"Appel G. Viral infections and the kidney: HIV, hepatitis B, and hepatitis C. Cleve Clin J Med. 2007;74:353\u2013360.","journal-title":"Cleve Clin J Med"},{"key":"5717_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(71)92572-4","volume":"2","author":"B Combes","year":"1971","unstructured":"Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet. 1971;2:234\u2013237.","journal-title":"Lancet"},{"key":"5717_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","volume":"324","author":"KN Lai","year":"1991","unstructured":"Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med. 1991;324:1457\u20131463.","journal-title":"N Engl J Med"},{"key":"5717_CR15","first-page":"79","volume":"13","author":"DN Amarapurkar","year":"1994","unstructured":"Amarapurkar DN, Dhawan P, Kalro RH. Role of routine estimation of creatinine clearance in patients with liver cirrhosis. Indian J Gastroenterol. 1994;13:79\u201382.","journal-title":"Indian J Gastroenterol"},{"key":"5717_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMra0809139","volume":"361","author":"P Gines","year":"2009","unstructured":"Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361:1279\u20131290.","journal-title":"N Engl J Med"},{"key":"5717_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486\u2013495.","journal-title":"Gastroenterology"},{"key":"5717_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/hep.24361","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91\u2013100.","journal-title":"Hepatology"},{"key":"5717_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2893.2009.01160.x","volume":"17","author":"A Tamori","year":"2010","unstructured":"Tamori A, Enomoto M, Kobayashi S, et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat. 2010;17:123\u2013129.","journal-title":"J Viral Hepat"},{"key":"5717_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/jgh.12499","volume":"29","author":"J Fung","year":"2014","unstructured":"Fung J, Seto WK, Lai CL, et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014;29:428\u2013434.","journal-title":"J Gastroenterol Hepatol"},{"key":"5717_CR21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1053\/j.ajkd.2005.02.010","volume":"45","author":"H Izzedine","year":"2005","unstructured":"Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45:804\u2013817.","journal-title":"Am J Kidney Dis"},{"key":"5717_CR22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/hupa.2001.25586","volume":"32","author":"N Tanji","year":"2001","unstructured":"Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001;32:734\u2013740.","journal-title":"Hum Pathol"},{"key":"5717_CR23","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/ki.2010.344","volume":"78","author":"MA Perazella","year":"2010","unstructured":"Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int. 2010;78:1060\u20131063.","journal-title":"Kidney Int"},{"key":"5717_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/labinvest.2009.14","volume":"89","author":"JJ Kohler","year":"2009","unstructured":"Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Investig. 2009;89:513\u2013519.","journal-title":"Lab Investig"},{"key":"5717_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96\u00a0weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u2013681.","journal-title":"J Hepatol"},{"key":"5717_CR26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","volume":"19","author":"HL Chan","year":"2012","unstructured":"Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732\u2013743.","journal-title":"J Viral Hepat"},{"key":"5717_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","volume":"146","author":"EJ Gane","year":"2014","unstructured":"Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146:138\u2013146.","journal-title":"Gastroenterology"},{"key":"5717_CR28","first-page":"826","volume":"32","author":"X Li","year":"2012","unstructured":"Li X, Zhong C, Yang S, et al. Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32:826\u2013829.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"5717_CR29","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S0168-8278(13)60085-9","volume":"20","author":"Y Wang","year":"2013","unstructured":"Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20:e37\u2013e46.","journal-title":"J Viral Hepat"},{"key":"5717_CR30","doi-asserted-by":"publisher","first-page":"95e1","DOI":"10.1016\/j.cmi.2015.05.035","volume":"22","author":"MC Tsai","year":"2016","unstructured":"Tsai MC, Chen CH, Tseng PL, et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016;22:95e1\u201395e7.","journal-title":"Clin Microbiol Infect"},{"key":"5717_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/jvh.12217","volume":"21","author":"M Lee","year":"2014","unstructured":"Lee M, Oh S, Lee HJ, et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat. 2014;21:873\u2013881.","journal-title":"J Viral Hepat"},{"key":"5717_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/AAC.45.1.229-235.2001","volume":"45","author":"ML Bryant","year":"2001","unstructured":"Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother. 2001;45:229\u2013235.","journal-title":"Antimicrob Agents Chemother"},{"key":"5717_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u2013398.","journal-title":"J Hepatol"},{"key":"5717_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247\u2013254.","journal-title":"Ann Intern Med"},{"key":"5717_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461\u2013470.","journal-title":"Ann Intern Med"},{"key":"5717_CR36","first-page":"S1","volume":"101","author":"KL Lentine","year":"2017","unstructured":"Lentine KL, Kasiske BL, Levey AS, et al. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation. 2017;101:S1\u2013S109.","journal-title":"Transplantation"},{"key":"5717_CR37","unstructured":"Services USDoHaH. Common terminology criteria for adverse events (CTCAE) version 5.0, 2017."},{"key":"5717_CR38","doi-asserted-by":"publisher","first-page":"8495","DOI":"10.1073\/pnas.88.19.8495","volume":"88","author":"SL Doong","year":"1991","unstructured":"Doong SL, Tsai CH, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine and related analogues. Proc Natl Acad Sci USA. 1991;88:8495\u20138499.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5717_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0166-3542(93)90050-S","volume":"21","author":"RA Heijtink","year":"1993","unstructured":"Heijtink RA, De Wilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 1993;21:141\u2013153.","journal-title":"Antiviral Res"},{"key":"5717_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1128\/AAC.35.2.394","volume":"35","author":"T Yokota","year":"1991","unstructured":"Yokota T, Mochizuki S, Konno K, et al. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother. 1991;35:394\u2013397.","journal-title":"Antimicrob Agents Chemother"},{"key":"5717_CR41","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1128\/AAC.41.7.1444","volume":"41","author":"SF Innaimo","year":"1997","unstructured":"Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997;41:1444\u20131448.","journal-title":"Antimicrob Agents Chemother"},{"key":"5717_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1365-2893.2000.00192.x","volume":"7","author":"C Ying","year":"2000","unstructured":"Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat. 2000;7:79\u201383.","journal-title":"J Viral Hepat"},{"key":"5717_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1681\/ASN.V113383","volume":"11","author":"ES Ho","year":"2000","unstructured":"Ho ES, Lin DC, Mendel DB, et al. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000;11:383\u2013393.","journal-title":"J Am Soc Nephrol"},{"key":"5717_CR44","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1128\/AAC.00437-06","volume":"50","author":"F Vidal","year":"2006","unstructured":"Vidal F, Domingo JC, Guallar J, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother. 2006;50:3824\u20133832.","journal-title":"Antimicrob Agents Chemother"},{"key":"5717_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1600-0676.1990.tb00440.x","volume":"10","author":"I Castillo","year":"1990","unstructured":"Castillo I, Bartolome J, Quiroga JA, et al. Detection of HBeAg\/anti-HBe immune complexes in the reactivation of hepatitis B virus replication among anti-HBe chronic carriers. Liver. 1990;10:79\u201384.","journal-title":"Liver"},{"key":"5717_CR46","first-page":"S34","volume":"35","author":"Y Takekoshi","year":"1991","unstructured":"Takekoshi Y, Tochimaru H, Nagata Y, et al. Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl. 1991;35:S34\u2013S39.","journal-title":"Kidney Int Suppl"},{"key":"5717_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11901-010-0042-6","volume":"9","author":"TM Chan","year":"2010","unstructured":"Chan TM. Hepatitis B and renal disease. Curr Hepat Rep. 2010;9:99\u2013105.","journal-title":"Curr Hepat Rep"},{"key":"5717_CR48","doi-asserted-by":"publisher","first-page":"e15074","DOI":"10.5812\/hepatmon.15074","volume":"14","author":"KH Liang","year":"2014","unstructured":"Liang KH, Chen YC, Hsu CW, et al. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glomerular filtration rates. Hepat Mon. 2014;14:e15074.","journal-title":"Hepat Mon"},{"key":"5717_CR49","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2165\/11204330-000000000-00000","volume":"70","author":"K McKeage","year":"2010","unstructured":"McKeage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs. 2010;70:1857\u20131883.","journal-title":"Drugs"},{"key":"5717_CR50","doi-asserted-by":"publisher","first-page":"955","DOI":"10.21873\/invivo.11334","volume":"32","author":"HE Wang","year":"2018","unstructured":"Wang HE, Lin CL, Pan TL, et al. Increase of serum kallikrein-8 level after long-term telbivudine treatment. Vivo. 2018;32:955\u2013960.","journal-title":"Vivo"},{"key":"5717_CR51","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u20131599.","journal-title":"Hepatology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05717-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-019-05717-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05717-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T07:46:13Z","timestamp":1650095173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-019-05717-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,6]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5717"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05717-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,6]]},"assertion":[{"value":"8 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"WK Seto is an advisory board member of Gilead Sciences and Bristol-Myers Squibb and received speaker fees from Gilead Sciences, Bristol-Myers Squibb, and Novartis. J Fung received research funding from Novartis. CL Lai received speaker fees from Bristol-Myers Squibb, Novartis and Gilead Sciences, and is an advisory board member of Gilead Sciences. MF Yuen received speaker fees from GlaxoSmithKline, Bristol-Myers Squibb, Novartis, and Gilead Sciences; and received research funding and is an advisory board member of Bristol-Myers Squibb, Novartis, and Gilead Sciences. The remaining authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}